PSTI Pluristem Therapeutics, Inc. featured news, full reports, and detailed charts
Pluristem Therapeutics, Inc. (PSTI) Wrap Up:
Pluristem Therapeutics, Inc., a bio-therapeutics company, engages in the production, research, and development of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders. It develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in the company’s proprietary PluriXTM three-dimensional bioreactor, which imitates the natural microstructure of bone marrow and does not require sup...www.pluristem.com
34 Employees
Founded in 2001
Pluristem Therapeutics, Inc. (PSTI:NASDAQ)
LAST $1.14 USD
CHANGE TODAY -0.02 -1.72%
VOLUME 72.7K
As of 3:59 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Pluristem Therapeutics, Inc. (PSTI)
|
OPEN
$1.16
|
PREVIOUS CLOSE
$1.16
|
|
|
DAY HIGH
$1.16
|
DAY LOW
$1.09
|
|
|
52 WEEK HIGH
01/30/09 - $2.29
|
52 WEEK LOW
12/1/08 - $0.30
|
|
|
MARKET CAP
21.1M
|
AVERAGE VOLUME 3 mo
91.9K
|
|
|
DILUTED EPS TTM
$-0.61
|
SHARES OUTSTANDING
18.5M
|
|
|
PSTI Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
PSTI Top Compensated Officers
Mr. Zami Aberman
Executive Chairman, Chief Executive Officer a...
Age: 55
Total Annual Compensation: $297.1K
Mr. Yaky Yanay
Chief Financial Officer, Principal Accounting...
Age: 38
Total Annual Compensation: $168.5K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Pluristem Therapeutics, Inc. (PSTI)
Pluristem Therapeutics, Inc. - Conference Presentation Call
10/20/2009
To discuss the clinical landscape of MSCs and its clinical trial for the treatment of critical limb ischemia and the placenta as an alternative and preferential source of MSCs
Pluristem Therapeutics, Inc. - Conference Presentation Call
09/29/2009
To discuss the company's innovative stem cell technology and its leading position in Israel's biotechnology industry
Pluristem Therapeutics Inc. Reports Earnings Results for the Fiscal Year Ended June 30, 2009
09/28/2009
Pluristem Therapeutics Inc. reported earnings results for the fiscal year ended June 30, 2009. Net loss was $6.63 million, up from $10.49 million for the previous fiscal year. Loss per share for the 2008-2009 fiscal year were $0.63, up from $1.63 for the previous fiscal year.
PSTI Competitors
| Company | Last | Change |
| Aastrom Biosciences Inc | $0.31 USD | 0.00 |
| Bioheart Inc | $0.89 USD | -0.01 |
| Medistem Inc | $0.19 USD | -0.145 |
| StemCells Inc | $1.09 USD | 0.00 |
| Thermogenesis Corp | $0.62 USD | -0.0125 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | PSTI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 4.6x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
PSTI |
||
|
PSTI transactions
| Type Date |
Target |
|
Private Placement
October 6, 2009 |
-- |
More Recent News About Pluristem Therapeutics, Inc.
Would you like to leave a comment about Pluristem Therapeutics, Inc. PSTI
Find out what social network information about Pluristem Therapeutics, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Pluristem Therapeutics, Inc. there is more great information available at Realpennies.com